197 related articles for article (PubMed ID: 8796554)
1. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
[No Abstract] [Full Text] [Related]
2. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Millefiorini E; Galgani S; Buttinelli C; Perciaccante G; Piazza G; Bozzao L; Fieschi C
J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595
[TBL] [Abstract][Full Text] [Related]
4. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
Stone LA; Frank JA; Albert PS; Bash CN; Calabresi PA; Maloni H; McFarland HF
Neurology; 1997 Sep; 49(3):862-9. PubMed ID: 9305355
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
[TBL] [Abstract][Full Text] [Related]
6. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b.
Richert ND; Ostuni JL; Bash CN; Duyn JH; McFarland HF; Frank JA
AJNR Am J Neuroradiol; 1998 Oct; 19(9):1705-13. PubMed ID: 9802494
[TBL] [Abstract][Full Text] [Related]
7. Nursing management of MS patients receiving interferon beta-1b therapy.
Costello K; Conway K
Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
[TBL] [Abstract][Full Text] [Related]
8. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis.
Tas MW; Barkhol F; van Walderveen MA; Polman CH; Hommes OR; Valk J
AJNR Am J Neuroradiol; 1995 Feb; 16(2):259-64. PubMed ID: 7726070
[TBL] [Abstract][Full Text] [Related]
9. Contemporary immunomodulatory therapy for multiple sclerosis.
Rudick RA
J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
[TBL] [Abstract][Full Text] [Related]
10. Spin-lock imaging in contrast-enhanced magnetic resonance imaging of human gliomas.
Aronen HJ; Peltonen TK; Tanttu JI; Sipilä LM; Ruhala MT; Jääskeläinen J; Sepponen R
Acad Radiol; 1996 Aug; 3 Suppl 2():S170-2. PubMed ID: 8796553
[No Abstract] [Full Text] [Related]
11. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
12. Interferon beta-1a in relapsing-remitting multiple sclerosis.
Blumhardt L
Hosp Med; 1999 Mar; 60(3):192-5. PubMed ID: 10476242
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect.
Petrella JR; Grossman RI; McGowan JC; Campbell G; Cohen JA
AJNR Am J Neuroradiol; 1996; 17(6):1041-9. PubMed ID: 8791914
[TBL] [Abstract][Full Text] [Related]
14. Serial study of neuropsychological performance and gadolinium-enhanced MRI in MS.
Mattioli F; Cappa SF; Cominelli C; Capra R; Marcianoc N; Gasparotti R
Acta Neurol Scand; 1993 Jun; 87(6):465-8. PubMed ID: 8356876
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
[TBL] [Abstract][Full Text] [Related]
17. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.
Thompson AJ; Miller D; Youl B; MacManus D; Moore S; Kingsley D; Kendall B; Feinstein A; McDonald WI
Neurology; 1992 Jan; 42(1):60-3. PubMed ID: 1734325
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
Khoury SJ; Weiner HL
Arch Intern Med; 1998 Mar; 158(6):565-73. PubMed ID: 9521220
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Gonzalez-Scarano F; Grossman RI; Galetta S; Atlas SW; Silberberg DH
Ann Neurol; 1987 Mar; 21(3):300-6. PubMed ID: 3606036
[TBL] [Abstract][Full Text] [Related]
20. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
